10-12 September 2018 //  Lancaster Royal Hotel, London


Garry Menzel

Dr Garry Menzel

CEO, TCR2 Therapeutics Inc

Dr. Menzel joined TCR2 in 2016 as a Director and Chief Executive Officer. He is a serial entrepreneur with over 20 years of experience in identifying innovative platforms and building healthcare businesses around them. He has also led multiple corporate transactions, including private financings, initial public offerings, licensing and M&A. Prior to TCR2, he was the Chief Strategy Officer at Axcella Health, the Chief Financial Officer at DaVita Healthcare (NYSE: DVA), and the Chief Operating Officer at Regulus Therapeutics (NASDAQ:RGLS). Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain & Company. Dr. Menzel earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a MBA from the Stanford Graduate School of Business.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad